# JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus

> **NCT05967520** · PHASE2 · UNKNOWN · sponsor: **Jemincare** · enrollment: 48 (estimated)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** JMKX000189
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05967520
- **Lead sponsor:** Jemincare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-21
- **Primary completion:** 2025-05
- **Final completion:** 2025-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05967520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05967520, "JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05967520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*